Summary of Compensation Arrangements for Named Executive Officers (Fiscal 2009–2010)
This document outlines the base salaries and bonuses for the named executive officers of Myriad Genetics, Inc. and its subsidiaries for fiscal years 2009 and 2010. It lists the compensation details for each executive, including the President and CEO, CFO, and other key officers. The summary also notes employment changes, such as Dr. Hobden's transfer to a new company and Dr. Skolnick's hourly compensation arrangement. The agreement sets forth the financial terms but does not specify additional employment conditions or benefits.
Exhibit 10.35
COMPENSATION OF NAMED EXECUTIVE OFFICERS
| Name and Position | Fiscal 2009 Base Salary ($) | Fiscal 2009 Bonus ($) | Fiscal 2010 Base Salary ($) | |||
| Peter D. Meldrum President and Chief Executive Officer | 800,000 | 1,000,000 | 832,000 | |||
| Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 550,000 | 415,000 | 565,000 | |||
| Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. (1) | 535,000 | 285,000 | N/A | |||
| James S. Evans Chief Financial Officer | 375,000 | 265,000 | 400,000 | |||
| Mark H. Skolnick, Ph.D. (2) Chief Scientific Officer | 520,000 | 135,000 | 530,000 | |||
| Richard Marsh Executive Vice-President, General Counsel and Secretary | 360,000 | 210,000 | 385,000 | |||
| (1) | As part of the separation of MPI on June 30, 2009, Dr. Hobden ceased his employment with Myriad Genetics and transferred to the new company as Chief Executive Officer, effective June 30, 2009 |
| (2) | Dr. Skolnick is compensated on an hourly basis. Base salary information reflects an annualized salary based on 2080 hours worked in a fiscal year. Actual amounts paid to Dr. Skolnick may vary significantly depending on the actual number of hours worked. |
